Medical research using Angimmune's technology in a Phase I clinical trial
Results from 30 patients in the Phase I trial was published in Haematologica, 2015 Jun;100(6):794-800. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma3.
These results have not established safety or clinical efficacy. However, a number of interesting observations have been made that will guide future studies. Several of these observations and their relevance to mechanisms are described below. This page will be updated when additional study results are published.
Sustained Effect Theory
This immunotoxin kills both malignant and normal T cells, however the normal T cells begin to repopulate within ten days from the periphery. This process is known as homeostatic proliferation. T cells repopulated by homeostatic proliferation may have different clonal distributions and different activities compared to previous states.1 In the study, patient number two was treated and reported as follows:
"Patient 2 is a 78-year-old male who developed CTCL in 2003 with a maculopapular
rash on his buttocks and a groin mass. Biopsy of both lesions showed T-cell
lymphoma. CT scan showed diffuse adenopathy. He received six cycles of chemotherapy
with cyclophosphamide, doxorubicin, vincristine, and methylprednisolone (CHOP
chemotherapy), but after several years the rash recurred. Biopsy again showed
CTCL. He did not have node or marrow involvement based on CT scans and bone
marrow biopsies and was staged as IB. He was treated with
The most likely theory for a sustained effect is that the anti-T cell immunotoxin acts in addition to killing malignant
T cells repopulated by homeostatic proliferation may have different clonal distributions and different activities compared to previous states. This raises the possibility that
In a monkey model of multiple sclerosis where foreign myelin basic protein induces
1.) The Journal of Immunology, 2008, 180:, Homeostatic Proliferation of Lymphocytes Results in Augmented Memory-Like Function and Accelerated Allograft Rejection.
2.) Current Drug Targets, 2009, 10, 104-109, Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous
3.) Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015.123711. Epub 2015 Mar 20.